Business
Notice of Cipher Pharmaceuticals Q2 2017 Conference Call
Notice of Cipher Pharmaceuticals Q2 2017 Conference Call Canada NewsWire MISSISS...
About this update from Cipher Pharmaceuticals Inc.
[{"type":"text","content":"\n\n\n\nNotice of Cipher Pharmaceuticals Q2 2017 Conference Call\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\n\nCanada NewsWire\nMISSISSAUGA, ON, July 25, 2017\n\n\n\nMISSISSAUGA, ON, July 25, 2017 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:CPH) (\"Cipher\" or \"the Company\") today announced the details of its Q2 2017 financial results conference call on Friday, August 11, 2017. \n\nQ2 2017 CONFERENCE CALL\n\nWHEN: Friday, August 11, 2017 at 8:30AM ET\n\nCONFERENCE CALL/WEBCAST: You can join the call by dialing 647-427-7450 or 1-888-231-8191. A live audio webcast will be available through www.cipherpharma.com or http://bit.ly/2uqaLR8. An archived replay of the webcast will be available for 90 days.\n\nAbout Cipher Pharmaceuticals Inc.\n\nCipher (TSX:CPH) is a specialty pharmaceutical company with a robust and diversified portfolio of commercial and early to late-stage products. Cipher acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products either directly in Canada and the U.S. or indirectly through partners in Canada, the U.S., and South America.  For more information, visit www.cipherpharma.com.   \nSOURCE Cipher Pharmaceuticals Inc.\n\n\n\nView original content: http://www.newswire.ca/en/releases/archive/July2017/25/c2179.html\n\n\n\n\nCraig Armitage, LodeRock Advisors, (416) 347-8954, [email protected] CNW Group 2017","length":2749,"tagName":"div"}]